| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma | TA985 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus | IPG789 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) | TA978 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome | HST31 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |